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Background: Extranodal NK/T-cell lymphoma (ENKL) is an aggressive hematological malignancy associated with
Epstein–Barr virus (EBV) infection. It is often resistant to conventional chemotherapy and has a poor prognosis.
Icaritin, a compound derived from Chinese herbal medicine, Herba Epimedii, has been reported to exert antitumor
effects on a variety of cancer cell lines. In the present study, we investigated the cytotoxic effects of Icaritin on the
two EBV-positive ENKL cell lines SNK-10 and SNT-8, along with the underlying molecular mechanisms.
Methods: ENKL cell lines SNK-10 and SNT-8 were exposed to different concentrations of Icaritin for the indicated
time. Treated cells were analyzed for cell proliferation, cell cycle, and cell apoptosis. Phosphorylation of Stat3 and
Akt proteins in signaling pathways and the EBV-encoded LMP1 proteins were measured by Western blot. Expression
of EBV genes was assessed by Real-Time PCR.
Results: Our results showed that Icaritin dose-dependently inhibits ENKL cell proliferation and induces apoptosis
and cell cycle arrest at G2/M phase. Additionally, Icaritin upregulates Bax, downregulates Bcl-2 and pBad, and activates
caspase-3 and caspase-9. The anti-proliferative and pro-apoptotic effects of Icaritin are likely mediated by inhibition of
Stat3 and Akt pathways through LMP1 downregulation. Importantly, Icaritin induces EBV lytic gene expression in ENKL
cells, and the combination of Icaritin and the antiviral drug ganciclovir (GCV) is more effective in inducing ENKL cells
apoptosis than Icaritin or GCV alone.
Conclusions: These findings indicate that EBV-targeted approaches may have significant therapeutic potential for ENKL
treatment.
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Extranodal NK/T-cell lymphoma (ENKL), a specific type
of peripheral T-cell lymphoma, is an aggressive malig-
nancy that frequently occurs in the nasal cavity and/or
upper aerodigestive tract [1]. ENKL accounts for about
10% of all peripheral T-cell lymphoma and has a higher
incidence in Asian and South American populations than
in Western countries [2]. Although ENKL is sensitive to
radiotherapy, it is inherently resistant to chemotherapy* Correspondence: bbchen@fudan.edu.cn; xywang@shmu.edu.cn
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unless otherwise stated.due to expression of p-glycoprotein, and consequently, it
has a poorer prognosis than other types of lymphoma
[3,4]. Therefore, new therapeutic strategies must be con-
sidered in order to improve the clinical outcome of this
aggressive malignancy.
Epstein–Barr virus (EBV), one of the most common
viruses in humans, is associated with several specific
forms of cancer [5]. Specifically, EBV is detected in
nearly all ENKL pathology specimens [6], and the geo-
graphic localization of ENKL matches the endemic distri-
bution of EBV [3], suggesting that EBV plays an essential
role in ENKL etiology. EBV has two distinct life cycles in
the human host; a lytic form that produces new infectious
virions, and a latent form that allows the virus to persist
in a dormant state in the host cell. Based on the expres-
sion of EBV-encoded genes, EBV in ENKL specimens is inis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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pattern [7].
Recently, new virus-targeted therapeutic approaches
have been exploited to treat EBV-associated malignan-
cies [8]. EBV encodes tyrosine kinases that phosphoryl-
ate and activate the antiviral drug, ganciclovir (GCV).
However, these viral kinases are only expressed during
the lytic cycle. Moore and co-workers have reported that
induction of EBV lytic reactivation followed by GCV
administration produces selective killing of EBV-positive
Burkitt’s lymphoma (BL) cells [9]. Recently, an increasing
number of reports have shown that activating the EBV
latent-lytic switch could be therapeutically beneficial for
EBV-associated tumors such as BL, nasopharyngeal car-
cinoma (NPC), and gastric carcinoma (GC) [10-12].
Arginine butyrate, a general histone deacetylase inhibitor
(HDACi), acts as an inducer of EBV lytic-phase gene
expression [13]. Arginine butyrate in combination with
GCV was used to treat refractory lymphomas in a
phase I/II clinical trial and achieved significant thera-
peutic results [14]. However to our knowledge, no
agent has been reported to effectively induce EBV lytic
re-activation in EBV-positive ENKL.
Icariin is a major active ingredient of the traditional
Chinese herbal medicine Epimedium. Icaritin (Figure 1A),
an intestinal metabolite of Icariin has been shown to
exhibit a variety of beneficial biological activities including
neuroprotective [15] and anti-inflammatory properties
[16,17]. Recent studies have shown that Icaritin also
exhibits anti-cancer properties. Icaritin inhibits growth
and induces apoptosis in breast and endometrial can-
cer cells through sustained ERK activation [18,19]. In
hematological malignancy, Icaritin strongly inhibits growth
of primary chronic myeloid leukemia (CML) cells in vitro
and in vivo by regulating the MAPK/ERK/JNK and JAK2/
STAT3/AKT pathways [20]. Icaritin also inhibits growth
and triggers apoptosis of acute myeloid leukemia (AML)
cells via downregulation of the MAPK/ERK and PI3K/
AKT signals [21]. However, it is not known whether
Icaritin possesses anti-ENKL activity.
In the present study, we found that Icaritin inhibited
growth and induced apoptosis and cell cycle arrest at
G2/M phase in the ENKL cell lines SNK-10 and SNT-8.
We also demonstrated that Icaritin is an effective in-
ducer of EBV lytic-phase gene expression in ENKL cell
lines, and Icaritin in combination with GCV induced
apoptosis in EBV-positive ENKL cells more effectively.
These findings suggest the potential clinical application
of Icaritin as a novel therapy against EBV-positive ENKL.
Materials and methods
Reagents
Icaritin was purchased from Shanghai Ronghe (Shanghai,
China). A stock solution was prepared by dissolvingIcaritin in DMSO (Sigma, Louis, MO, USA) and stored
at −20°C. The final concentration of DMSO in the treat-
ment medium was controlled below 0.1%. GCV was pur-
chased from Hubei Ke Yi Pharmaceutic Co., Ltd (Hubei,
China). Antibodies against caspase-9, caspase-3, Bax, Stat3,
and p-Stat3 (pY705) were purchased from Epitomics
(Burlingame, CA, USA). Antibodies against Bcl-2 and
pAkt (Ser473) were from Cell Signaling Technology
(Boston, MA, USA). Antibodies against Bad (F130) and
pBad (S136) were from Bioworld Technology, Inc. (Louis
Park, MN, USA). LMP1 antibody and HRP-conjugated
goat anti-mouse/rabbit secondary antibody were from
Abcam (Cambridge, MA, USA). EBV Zta antibody was from
Santa Cruz biotechnology (Dallas, TX, USA). β-Tubulin
antibody was from Beijing CoWin Bioscience Co., Ltd
(Beijing, China).
Cells and cell culture
The ENKL cell lines, SNK-10 and SNT-8, were provided
by Dr. Norio Shimizu at Tokyo Medical and Dental
University. SNK-10 was established from the periph-
eral blood of an ENKL patient with chronic active EBV
infection [22]. SNT-8 was derived from primary lesions
of a Japanese patient with EBV-positive ENKL [23].
SNK-10 and SNT-8 cells were cultured in RPMI-1640
(Hyclone) media supplemented with 10% heat-inactivated
human plasma, 1% penicillin-streptomycin, and 700 U/ml
of recombinant human interleukin-2 (IL-2) (Peprotech,
Rochy Hill, NJ, USA).
Cell viability and proliferation assays
Cell viability was measured using the CCK-8 assay
(Beyotime, Shanghai, China) following manufacturer’s
instructions. The percent of viable cells was calculated
using the formula: ratio (%) = [OD (Treatment) – OD
(Blank)]/[OD (Control) – OD(Blank)] × 100. Each ex-
periment was carried out in six replicates and results
were calculated over three independent experiments.
Cell proliferation was determined using the CFDA-SE
Cell Proliferation Assay (Beyotime). Cells were stained with
carboxyfluorescein diacetate succinimidyl ester (CFDA-SE)
according to manufacturer’s instructions and cultured in
six-well plates with various concentrations of Icaritin for
48 h. CFDA-SE dilution was analyzed by flow cytometry
on a FACSCalibur (BD Biosciences, CA, USA) and data
were analyzed using the FlowJo software (Treestar,
Ashland, OR, USA).
Cell cycle analysis
Cells were incubated with vehicle (0.1% DMSO) or differ-
ent concentrations of Icaritin for 48 h, harvested, and fixed
by incubation in 70% ethanol (500 μl) at 4°C overnight.
Cells were then collected by centrifugation at 900Xg for
5 min and washed with PBS. Subsequently, cells were
Figure 1 Icaritin exhibits cytotoxicity on ENKL cells. A. The chemical structure of Icaritin. B. Effects of Icaritin on SNK-10 and SNT-8 cell viability
by the CCK-8 assay. (a) IC50 curves after 72 h treatment (n = 3); (b) Time- and dose–response curves (n = 3). C. Effects of Icaritin on SNK-10 and
SNT-8 cell proliferation. Cell proliferation was determined by the CFDA-SE assay after 48 h treatment. (a) CFDA-SE flow cytometry histograms;
(b) The mean cellular florescence intensity (MFI) (n = 3). *p < 0.05, #p < 0.01 vs control.
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at 37°C for 30 min, and then with 400 μl propidium iodide
(PI) at 4°C for 30 min in the dark. DNA content wasanalyzed on a FACSCalibur flow cytometer and data were
analyzed using the Modfit LT 3.2 software (Verity Software
House, ME, USA).
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Cells were seeded in six-well plates and incubated with
various concentrations of Icaritin for 48 h. Cell apoptosis
was determined using the annexin V-FITC apoptosis kit
(BestBio, Shanghai, China) following manufacturer’s in-
structions. Cells were analyzed on a FACScan flow cyt-
ometer (BD Biosciences) and data were interpreted
using the Flowjo software (Treestar).
Analysis of nuclear morphology
Cells were incubated with Icaritin or vehicle for 48 h,
harvested, and fixed by incubating in stationary liquid
for 10 min at room temperature. After being washed
twice with PBS, cells were stained with Hoechst-33258
(Beyotime) and examined by confocal florescence micros-
copy (Nikon, Tokyo, Japan). The apoptotic cells exhibited
nuclear shrinkage, and condensed, fragmented chromatin
structure as well.
Real-Time PCR
Total RNA was extracted using Trizol Reagent (Invitrogen,
Carlsbad, CA, USA) following manufacturer’s instructions.
cDNA was synthesized using PrimeScript RT Master Mix
(Perfect Real Time) (Takara, Tokyo, Japan) and subjected
to Real-Time PCR using a SYBR Premix Ex Taq (Tli RNa-
seH Plus) (Takara) on a 7500 Real-Time PCR System (ABI,
Grand Island, NY, USA). All reactions were performed in
duplicate. Primers used for Real-Time PCR are shown in
Table 1.
Western blot analysis
Cells following treatment were lysed with RIPA (Beyo-
time) in the presence of the protease inhibitor PMSF
(Beyotime). Protein concentration was determined using
the BCA protein assay kit (Beyotime). Protein samples
(30 μg each) were separated by SDS-PAGE and trans-
ferred to PVDF membranes (Immobilon-P membrane;Table 1 Primers used for Real-Time PCR












EBNA1-R CCCCTCGTCAGACATGATTCMillipore, USA). After incubation in 5% fat-free milk at
room temperature for 2 h to block non-specific binding,
membranes were incubated with primary antibodies in
TBS-Tween (TBST) (0.05% Tween-20 in TBS) at 4°C
overnight. Membranes were then washed three times
with TBST and incubated with secondary antibody for
1 h at room temperature. Membranes were again washed
three times with TBST and visualized by enhanced
chemiluminescence using Supersignal West Pico Trial
Kit (Thermo Scientific, Massachusetts, USA).
Statistical analysis
Results are presented as means ± standard deviation
(SD). The dose–response analyses were performed by
one-way ANOVA with Dunnett’s-t test. Cell apoptosis
rate was entered into 2 × 2 factorial design with Icaritin
and GCV as between-subject factors. All statistical ana-
lyses were performed using the software Stata 12.0 for
windows. Differences with p < 0.05 were considered
statistically significant.
Results
Icaritin exhibits cytotoxicity towards ENKL cells in vitro
We first investigated the effects of Icaritin on SNK-10
and SNT-8 cell viability using the CCK-8 assay. We found
that Icaritin decreased SNK-10 and SNT-8 cell viability in
a time and dose-dependent manner (Figure 1B-b), with an
IC50 of 28 μM toward SNK-10 cells and 6.5 μM toward
SNT-8 cells after 72 h treatment (Figure 1B-a). We further
examined the effects of Icaritin on ENKL cell proliferation
using the CFDA-SE cell proliferation assay. SNK-10 and
SNT-8 cells were stained with CFDA-SE and incubated
with Icaritin for 48 h. Cell proliferation was determined by
analysis of CFDA-SE dilution on a flow cytometer. CFDA-
SE histograms showed that Icaritin dose-dependently
increased cellular florescence intensity of SNK-10 and
SNT-8 cells (Figure 1C-a), indicating that Icaritin
inhibited SNK-10 and SNT-8 cell division. Specifically,
Icaritin at 20, 30, and 50 μM significantly increased the
mean florescence intensity (MFI) of SNK-10 cells to
451.7 (p < 0.05), 767.3 (P < 0.01), and 1039.3 (P < 0.01),
respectively, compared with 164.3 of untreated cells
(Figure 1C-b). Similar to results from the cell viability
assay, SNT-8 cells were more sensitive to Icaritin-induced
growth inhibition compared with SNK-10 (Figure 1C-b).
Collectively, these results indicated that Icaritin exhibits
cytotoxicity towards ENKL cells in vitro.
Icaritin induces cell cycle arrest at G2/M phase in ENKL
cells
We evaluated the effects of Icaritin on cell cycle distri-
bution of SNK-10 and SNT-8 by flow cytometry with PI
staining. Our data showed that Icaritin treatment signifi-
cantly increased the proportion of cells at G2/M phase,
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S phase (Figure 2). Specifically, untreated SNK-10 and
SNT-8 cells had only 3.5% and 0.6% cells, respectively,
at G2/M phase. Treatment of SNK-10 and SNT-8 cells
with 50 μM and 32 μM Icaritin significantly increased
the proportion of cells at G2/M phase to 22.4% and
24.1%, respectively. Moreover, while untreated SNK-10
and SNT-8 cells had 63.7% and 56.7% cells at S phase,
respectively, treatment with 50 μM and 32 μM Icaritin
significantly reduced the proportion of cells at S phase
to 42.2% and 36.5%, respectively (Figure 2B). These results
suggested that Icaritin inhibits ENKL cell proliferation
through inducing cell cycle arrest at G2/M phase.
Icaritin induces apoptosis in ENKL cells
Many chemotherapeutic agents promote cancer cell apop-
tosis. We investigated the effects of Icaritin on ENKL cell
apoptosis using annexin V/PI dual staining flow cytome-
try. Our data showed that Icaritin induced apoptosis in
both SNK-10 and SNT-8 cells (Figure 3A and B). As
shown in the flow cytometry histograms (Figure 3A),Figure 2 Icaritin induces cell cycle arrest at G2/M phase in ENKL cells.
cytometry with PI staining after 48 h treatment. A. Representative flow cyto
the cell cycle (n = 3). *p < 0.05, #p < 0.01 vs control.Icaritin dose-dependently increased the population of
early and late apoptotic cells. While untreated SNK-10
and SNT-8 cells each had about 10% apoptosis, SNK-10
cells treated with 50 μM Icaritin showed 32% apoptosis,
and SNT-8 cells treated with 32 μM displayed 58% apop-
tosis (Figure 3B). These results indicated that Icaritin
induces apoptosis in ENKL cells.
We also studied the effects of Icaritin on ENKL cell
morphology. The blue fluorescent Hoechst dyes are cell
permeable nucleic acid stains that are very sensitive to
DNA conformation and chromatin state in cells. Conse-
quently, they can detect gradations of nuclear damage.
After 48 h treatment with Icaritin, SNK-10 and SNT-8
cells were stained with Hoechst 33258 and examined by
florescence microscopy. As shown in Figure 3C-a, SNK-
10 and SNT-8 cells treated with Icaritin exhibited apop-
totic morphological characteristics such as cell shrinkage
and chromatin condensation and fragmentation, while
these morphological features were not evident in un-
treated cells. In addition, the percent of apoptotic cells
determined by morphology-based cell sorting (Figure 3C-b)Cell cycle distribution of SNK-10 and SNT-8 cells was analyzed by flow
metry histograms. B. Cell distribution at G0/G1, S, and G2/M phases of
Figure 3 Icaritin induces ENKL cell apoptosis. Cell apoptosis of SNK-10 and SNT-8 was analyzed by flow cytometry and florescence microscopy,
respectively, after 48 h treatment with Icaritin. A. Representative histograms of annexin V-FITC/PI double-staining flow cytometry. B. Percent apoptosis
(including early and late apoptotic cells) determined by flow cytometry (n = 3). C. Cell apoptosis assessed by florescence microscopy. Cells were stained
with Hoechst 33258. (a) Cell and nuclear morphology by florescence microscopy (magnification 400×). The arrows indicate the cells undergoing
apoptosis; (b) Percent apoptosis determined by morphology-based cell sorting (n = 3). At least 1,000 cells from five randomly selected fields
were counted for each data point. *p < 0.05, #p < 0.01 vs control.
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flow cytometry (Figure 3B).Icaritin induces caspase activation in ENKL cells
To investigate the mechanisms underlying Icaritin’s pro-
apoptotic effects in ENKL cells, we determined the levels
of caspases and the Bcl-2 family proteins by western blot
analysis. Our results showed that Icaritin dose-dependently
increased levels of cleaved caspase-9 and caspase-3 in
SNK-10 and SNT-8 cells (Figure 4). We also found thatFigure 4 Effects of Icaritin on caspases and Bcl-2 family proteins
in ENKL cells. SNK-10 and SNT-8 cells were subjected to western blot
analysis after 48 h treatment with Icaritin. β-tubulin was used as an
internal control. Representative blots are shown.Icaritin down-regulated Bcl-2 and p-Bad and up-regulated
Bax in both cell lines while having no significant effects on
Bad expression (Figure 4). Collectively, these results sug-
gested that Icaritin induces ENKL cell apoptosis through
activating the mitochondria-mediated caspase pathway.Figure 5 Effects of Icaritin on Stat3 and Akt signaling pathways
in ENKL cells. Protein levels in SNK-10 and SNT-8 cells were determined
by western blot analysis after treatment. A. Cells were treated
with Icaritin at indicated concentrations for 48 h. B. Cell were
treated with 30 μM (SNK-10) or 16 μM (SNT-8) Icaritin for indicated
time. β-tubulin was used as an internal control. Representative
blots are shown.
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To further investigate the mechanisms of action of
Icaritin, we analyzed the effects of Icaritin on the pro-
liferative and survival signals Stat3 and Akt in ENKL
cells. After 48 h treatment with Icaritin, SNK-10 and
SNT-8 cells were lysed and subjected to western blot
analysis. As shown in Figure 5, Icaritin reduced p-
Stat3 and p-Akt levels in a dose- and time-dependent
manner in both cell lines without affecting the level of
total Stat3. These results suggested that Icaritin in-
hibits growth and induces apoptosis in ENKL cells
likely through regulation of the Stat3 and Akt signaling
pathways.Figure 6 Effects of Icaritin on LMP1 expression in ENKL cells. A-a (B-a
concentrations for 48 h and LMP1 mRNA level was determined by Real-T
indicated concentrations for 48 h and LMP1 protein level was determined by
with 30 μM (16 μM) Icaritin for indicated time and LMP1 mRNA level was det
treated with 30 μM (16 μM) Icaritin for indicated time and LMP1 protein levelIcaritin reduces LMP1 mRNA and protein expression in
ENKL cells
EBV-encoded LMP1 protein activates proliferative and
survival signals including NF-κB, MAPK, JAK/STAT,
and AKT to regulate the proliferation, immortalization,
and invasion of infected lymphoma cells [24-26]. We ex-
amined the effects of Icaritin on LMP1 mRNA and pro-
tein expression in ENKL cells by Real-Time PCR and
western blot analysis, respectively. We found that after
48 h treatment, Icaritin at 30 μM and 50 μM signifi-
cantly reduced LMP1 mRNA and protein expression in
SNK-10 cells (Figure 6A-a and A-b). We also found that
Icaritin at 30 μM inhibited LMP1 mRNA and protein). SNK-10 cells (SNT-8 cells) were treated with Icaritin at indicated
ime PCR. A-b (B-b). SNK-10 cells (SNT-8 cells) were treated with Icaritin at
western blot analysis. A-c (B-c). SNK-10 cells (SNT-8 cells) were treated
ermined by Real-Time PCR. A-d (B-d). SNK-10 cells (SNT-8 cells) were
was determined by western blot analysis. *p < 0.05, #p < 0.01.
Figure 7 (See legend on next page.)
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Figure 7 Icaritin induces EBV lytic-phase gene expression and sensitizes ENKL cells to GCV treatment. A-a (B-a). ENKL cells were treated
with Icaritin at indicated concentrations for 48 h and the mRNA levels of EBV-encoded genes (BZLF1, BRLF1, BMRF1, and EBNA1) were determined
by Real-Time PCR (n = 3). *p < 0.05, #p < 0.01 vs control. A-b (B-b). SNK-10 cells (SNT-8 cells) were treated with 50 μM (32 μM) Icaritin or
DMSO for indicated time and the mRNA levels of EBV-encoded genes (BZLF1, BRLF1, BMRF1, and EBNA1) were determined by Real-Time
PCR (n =3). *p < 0.05, #p < 0.01 vs control. A-c (B-c). SNK-10 cells (SNT-8 cells) were treated with Icaritin at indicated concentrations for 48 h
and the protein level of the IE protein Zta was determined by western blot analysis. A-d (B-d). Icaritin sensitizes ENKL cells to GCV treatment.
SNK-10 and SNT-8 cells were treated respectively with Icaritin, GCV, or both for 48 h and the cell apoptosis was determined by flow cytometry with
annexin V-FITC/PI double-staining (n = 3). #p < 0.01.
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reduction observed after 24, 48, and 72 h incubation
(Figure 6A-c and A-d). As the Figure 6B shown, Icaritin
reduced LMP1 mRNA and protein expression in a dose-
and time-dependent manner in SNT-8 cells. These data
suggested that the inhibitory effects of Icaritin on Stat3
and Akt signaling in ENKL cells might be mediated by
downregulation of LMP1 expression.
Icaritin induces EBV lytic-phase gene expression and
sensitizes ENKL cells to GCV treatment
Finally we studied the effects of Icaritin on EBV latent-
lytic switch in ENKL cells by analyzing the mRNA ex-
pression of three lytic-phase genes and one latent-phase
gene. The three lytic-phase genes included the two EBV
immediate early (IE) genes BZLF1 and BRLF1, and the
early gene BMRF1. The latent-phase gene EBNA1 is
expressed in EBV at all latency stages. After 48 h treat-
ment, Icaritin significantly induced the mRNA expres-
sion of the three lytic-phase genes (BZLF1, BRLF1, and
BMRF1), and inhibited the mRNA expression of the
latent-phase gene (EBNA1) in a dose-dependent manner
(Figure 7A-a and B-a). In addition, a time-course study
showed that 50 μM Icaritin for SNK-10 and 32 μM for
SNT-8 significantly upregulated the three lytic genes and
downregulated the latent gene after 12, 24, 48, and 72 h
incubation (Figure 7A-b and B-b). Since expression of
EBV IE protein Zta (also referred to as BZLF1, ZEBRA,
Z or EB1) is sufficient to activate the entire cascade of
lytic EBV infection, we examined the expression of Zta
(BZLF1) protein after Icaritin treatment. Similar to the
effects observed on the mRNA expression, Icaritin dose-
dependently increased the Zta protein expression in
both cell lines (Figure 7A-c and B-c). Taken together,
these results suggested that Icaritin promotes lytic EBV
infection in EBV-positive ENKL.
Since EBV-encoded tyrosine kinases expressed during
the lytic cycle phosphorylate and convert the antiviral
prodrug GCV into its active form, we speculated that
Icaritin might sensitize ENKL cells to GCV treatment
through induction of lytic EBV infection. Indeed, we
found that treatment of ENKL cells simultaneously with
Icaritin (50 μM for SNK-10 and 32 μM for SNT-8) and
GCV (25 μg/ml) for 48 h triggered significantly moresevere apoptosis than with either Icaritin or GCV alone
(Figure 7A-d and B-d).
Discussion
Extranodal natural killer/T-cell lymphoma (ENKL) is a
highly aggressive hematological malignancy associated
with Epstein–Barr virus (EBV) infection. It is often re-
sistant to conventional chemotherapy and new thera-
peutic approaches need to be considered to achieve
better clinical outcome [27]. Icaritin is a compound
derived from Chinese herbal medicine Herba Epimedii,
which is traditionally used in East Asian countries to im-
prove bone health [28] and treat menopausal symptoms
[29]. Recently, Icaritin has been reported to exert antitu-
mor effects on various cancer cell lines. In this study, we
investigated the cytotoxic effects of Icaritin on the EBV-
positive ENKL cell lines SNK-10 and SNT-8.
We found that Icaritin effectively inhibited cell viabil-
ity of the two ENKL cell lines with IC50 values of 28 μM
and 6.5 μM for SNK-10 and SNT-8, respectively, after
72 h treatment. The inhibitory effects of Icaritin on the
two ENKL cell lines were also observed on proliferation
index in a CFDA-SE proliferation assay. Furthermore,
our results from flow cytometry analysis demonstrated
that Icaritin induced cell apoptosis and G2/M arrest in
SNK-10 and SNT-8, similar to previously reported
effects of Icaritin on breast cancer cells [18,30].
Icaritin has been reported to inhibit growth and in-
duce apoptosis in cancer cells through several mecha-
nisms that include: 1) upregulation of pro-apoptotic
proteins (i.e. Bax and Bak) and downregulation of anti-
apoptotic proteins (i.e. Bcl-2) [19,31]; and 2) inhibition
of PI3K/AKT, Jak/Stat, and MAPK/ERK signaling path-
ways [20,21]. In this study, we found that Icaritin upreg-
ulated pro-apoptotic protein Bax and downregulated
anti-apoptotic protein Bcl-2 and p-Bad, along with
cleaved caspase-3 and cleaved caspase-9. These results
suggested that mitochondria-mediated caspase cascade
plays a major role in Icaritin-induced ENKL cell apoptosis.
Proliferative and survival Stat3 and Akt pathways are
activated in ENKL cell lines as well as in the neoplastic
cells of most ENKL primary tumors [32,33]. Inhibition
of activated Stat3 in the ENKL cell line MEC04 induced
cell death. Additionally, treatment of MEC04 with the
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with decreased level of p-Stat3 [34]. Phosphorylated Akt
is detected in ENKL [35]. Treatment of NK-92 with
the PI3K inhibitor LY294002 resulted in a reduction of
p-Akt and cell apoptosis [36]. Taken together, these
studies highlight the importance of JAK/STAT and
PI3K/AKT pathways in ENKL survival, and thus tar-
geting Stat and Akt might be an effective therapeutic
approach for ENKL. In this present study, we found
that Icaritin reduced levels of p-Stat3 and p-Akt in
SNK-10 and SNT-8, suggesting that the inhibitory
effects of Icaritin on ENKL cells are mediated by inhib-
ition of the Jak/Stat3 and Akt signaling pathways.
EBV-encoded LMP1 protein activates Stat3 and Akt in
EBV-associated malignancies including B cell lymphoma
[37], NPC [38], and ENKL [39]. Interestingly, we found
that Icaritin downregulated the mRNA and protein
levels of LMP1 in ENKL cells, suggesting that the inhibi-
tory effects of Icaritin on Stat3 and Akt might be medi-
ated by reduction of LMP1 expression.
Recent studies have shown that specific chemotherapeu-
tic agents induce EBV lytic replication in EBV-positive
cancer cells [12,40], and by doing so, sensitize cancer cells
to nucleoside antiviral agents [13]. Reactivation of EBV
lytic cycle begins with the expression of the EBV im-
mediate early (IE) viral gene BZLF1, which encodes the
transcriptional activator Zta [41,42]. Zta subsequently
activates the other IE gene BRLF1 [43]. BZLF1 and
BRLF1 together activate the early lytic gene BMRF1,
which encode viral proteins responsible for replication
[44]. In this study, we found that Icaritin at 50 μM and
32 μM for SNK-10 and SNT-8, respectively, signifi-
cantly induced expression of the EBV lytic genes BZLF1,
BRLF1, and BMRF1 after 48 h incubation. In addition, our
time-course study showed that Icaritin significantly in-
creased EBV lytic gene expression after 12 h – 72 h incu-
bation in both cell lines. Sivachandran et al. [45] reported
that depletion of EBV viral gene EBNA1 in latently in-
fected cells positively contributes to spontaneous EBV re-
activation, showing that EBNA1 has a role in suppressing
re-activation. In this study, we found that Icaritin signifi-
cantly reduced the expression of EBNA1 in SNK-10 and
SNT-8. Collectively, these results suggested that Icaritin
activates EBV lytic replication in ENKL cells.
During the EBV lytic cycle, viral kinases are expressed
that phosphorylate the antiviral pro-drug GCV into its
active cytotoxic form [46]. Phosphorylated GCV, a nu-
cleoside analogue, inhibits not only the viral DNA poly-
merase but also the host cell DNA polymerase, and
thereby kills both EBV and EBV-infected cancer cells
[42]. Therefore, agents inducing lytic EBV infection sensitize
tumor cells to GCV treatment [8]. In the present study, we
showed that the combination of GCV and Icaritin was much
more effective in inducing ENKL cell apoptosis than eitheragent alone. To our knowledge, this is the first report that
Icaritin activates lytic EBV infection and sensitizes ENKL to
GCV treatment.
In summary, we demonstrate that Icaritin inhibits cell
proliferation and induces cell apoptosis and cell cycle ar-
rest at G2/M phase in ENKL cells. These effects are pos-
sibly mediated by inhibition of Jak/Stat3 and PI3K/AKT
pathways via downregulation of LMP1. In addition, Icar-
itin activates lytic EBV infection and sensitizes ENKL
cells to antiviral treatment by GCV. Our results provide
rationale that EBV-targeted agents have therapeutic po-
tential for ENKL treatment.
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